ADVA
8.9.2020 09:02:18 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Luxembourg Commercial Internet Exchange (LU-CIX) is increasing the security and availability of its services with the ADVA ALM fiber monitoring solution. The technology provides real-time network visibility, enabling LU-CIX to quickly locate and resolve all fiber issues. Deployed in the internet exchange company’s backbone infrastructure, the ADVA ALM delivers comprehensive in-service assurance. It’s now empowering LU-CIX to accurately pinpoint areas of degradation, instantly initiate countermeasures and redirect traffic away from degraded optical paths. The compact and low-power solution helps avoid outages and enables LU-CIX to track its SLAs. ADVA’s partner Telindus, a brand of Proximus Luxembourg, also played a key role in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005221/en/
“We needed a solution that delivers precise, automated, up-to-the-minute root-cause analysis combined with permanent measurement. That’s why we chose the ADVA ALM. It enables our team to tackle issues more quickly and efficiently, while also addressing an area of security exposure,” said Michel Lanners, CIO, LU-CIX. “One of the key advantages of the ADVA ALM is that it offers significant improvement without a major addition to our existing network. It delivers total insight and full control without significant investment. What’s more, the technology enables us to improve the integrity of our network and detect eavesdropping attacks. With the ADVA ALM, we can remotely measure attenuation and stay one step ahead of attacks using a splitter or bending coupler.”
The ADVA ALM is now delivering precise, real-time insight into the integrity and performance of LU-CIX’s optical transport infrastructure. With its ease of use and intuitive GUI, the in-service monitoring equipment provides complete network assurance, enabling the root cause of link outages to be immediately pinpointed. Issues can now be identified in seconds and the right measures engaged, saving the company both time and money. The ADVA ALM also makes it straightforward to separate faults with active devices from problems in the fiber plant. Another key advantage is its transparent, service-agnostic monitoring, which is completely independent of transported data. That means the ADVA ALM delivers complete assurance with no application interference.
“Our ALM now ensures that LU-CIX has an intricate understanding of its fiber network. For maintenance teams, that means no more false alarms, no unnecessary site visits and no wasted hours finding faults. Now problems can be diagnosed and dealt with long before they affect services. Not only will this help to reduce operational expenses and maximize resource efficiency, but it’s also a key tool for maintaining valuable SLAs,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “LU-CIX is crucial to Luxembourg’s internet sector and one of Europe’s key internet hubs. By harnessing our unique plug-and-play device to further enhance the stability and efficiency of its infrastructure, it can continue to provide a secure and trusted environment in the heart of Europe.”
“This deployment is already bringing major benefits to LU-CIX and its customers. It’s enabling the internet exchange to avoid performance issues by rapidly responding to defects and degradation in its fiber network. Now LU-CIX can proactively reroute traffic and operating teams can take targeted action to fix faults,” said William Malingrey, pre-sales consultant, network solutions, Telindus. “We’re committed to providing the most innovative technologies available to support our customers’ business strategies and digital transformation. The ADVA ALM is a uniquely affordable and space-efficient solution that makes a real difference. It’s now giving LU-CIX total visibility and control of its fiber assets and supporting simpler, more cost-efficient and more sustainable practices.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About LU-CIX
LU-CIX, the LUxembourg Commercial Internet eXchange was founded in 2009 based on a not-for-profit membership association with an open and neutral philosophy. Its aim is to develop the Internet and support the data center community in Luxembourg. As well as providing the technical infrastructure LU-CIX also makes a major contribution to the Luxembourg Internet community through its leading industry event, Luxembourg Internet Days, which takes place in November every year and attracts over a thousand industry experts and decision makers from around the globe. LU-CIX also runs the datacenters-in-europe.com website, which provides a shared communication platform for all the players in the Luxembourg data center and Internet arena and promotes Luxembourg as the best place for your European data center and ICT business in the heart of Europe. More information at www.lu-cix.lu .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005221/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom